Apr 14, 2008

Boehringer Ingelheim reviews cough medicine in China

SHANGHAI German pharmaceutical company Boehringer Ingelheim has called a creative review of its US$5 million Mucosolvan cough medicine brand in China, with four agencies, including incumbent Publicis and Y&R, believed to be competing for the account.

Boehringer Ingelheim reviews cough medicine in China
Mucosolvan is the world’s leading cough expectorant.

While Boehringer Ingelheim develops a range of chemical products, including animal health treatments and biopharmaceuticals, human pharmaceuticals account for 95 percent of the company’s sales.

Source:
Campaign Asia
Tags

Related Articles

Just Published

2 hours ago

Agency Report Card 2024: Publicis Media

Publicis Media came in swinging in 2024—snagging big-name clients, racking up awards and riding a wave of regional growth. But with rivals regrouping and the AI race tightening, the fight for APAC dominance is far from over.

3 hours ago

How a Chinese gold brand is glittering from the 618 ...

Laopu Gold posted impressive sales figures during the 618 shopping festival, setting the potential for further growth and brand expansion by tapping Chinese cultural identity.

3 hours ago

Uber launches 'Ride Offers' letting brands pay for ...

As part of its expanding ad portfolio, Uber has introduced Ride Offers, a feature that rewards riders with ride discounts when they engage with targeted adverts in the app.

2 days ago

'Looking for the first domino': Titanium jury ...

In a wide-ranging interview, John explains how APAC work, like New Zealand’s stigma-smashing Grand Prix for Good and Ogilvy Singapore’s work for Vaseline, are setting the stage for global creative change.